Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Vanguard Total International Stock Index Fund ETF trades at $84.32. Which is the better fit depends on your goals.
| ABEO | VXUS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $87.06 |
52-Week Low | $4.17 | $68.24 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VXUS trades at $86.17, up 1.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides diversified international equity exposure across developed and emerging markets, holding over 8,700 stocks. Recent news highlights its role in portfolio diversification amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
VXUS offers a strategic hedge against U.S. market concentration, trading at a discount to domestic peers. Key risks include currency fluctuations, geopolitical tensions, and emerging market volatility. Analyst sentiment is positive due to broad diversification and cost efficiency, though performance depends on global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
